Pieris Pharmaceuticals(PIRS) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Palvella's recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Expanded QTORIN™ rapamycin's development into clinically significant angiokeratomas, a rare and debilitating lymphatic disease with no FDA-approved therapies, with Phase 2 study initiation anticipated in second ...